Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Gustav Stålhammar MD, PhD

Gustav Stålhammar MD, PhD

Associate Professor of Ophthalmology, Ophthalmologist and Pathologist, St. Erik Eye Hospital and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Dr. Gustav Stålhammar is an Associate Professor of Ophthalmology and the Director of the St. Erik Ophthalmic Pathology Laboratory at St. Erik Eye Hospital in Stockholm, Sweden. He also holds a research group leader position at the Department of Clinical Neuroscience, Karolinska Institutet. Dr. Stålhammar is a board-certified ophthalmologist and pathologist, making him uniquely qualified as Sweden's only practicing ophthalmic pathologist.

Dr. Stålhammar’s research focuses on predicting and preventing death from ocular tumors, particularly uveal melanoma, the most common primary intraocular tumor in adults. His work aims to understand and combat the high mortality rates associated with micrometastases, which can remain dormant for years before causing fatal metastasis. He is the Principal Investigator of the world's longest randomized trial of adjuvant treatment for uveal melanoma (AMUM), a study that seeks to improve survival outcomes for patients with this aggressive cancer.

In addition to his work on uveal melanoma, Dr. Stålhammar is expanding knowledge about retinoblastoma, the most common intraocular tumor in children. Through national and international collaborations, his research investigates how chromosomal and genetic aberrations influence survival and utilizes digital image analysis to identify prognostic markers.

Dr. Stålhammar has published 70 peer-reviewed original articles, six book chapters, three review articles, and six other articles. He serves on the board of two foundations: the Edwin Jordan Foundation for Ophthalmological Research and the Fru Karin Sandqvist Foundation. Dr. Stålhammar is a member of the Swedish Melanoma Study Group and participates in collaborative research projects with leading national and international institutions.